|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
EP2083081A1
(en)
|
2005-07-22 |
2009-07-29 |
Five Prime Therapeutics, Inc. |
Compositions and methods of treating disease with FGFR fusion proteins
|
|
ES2582652T3
(es)
*
|
2006-02-10 |
2016-09-14 |
Genentech, Inc. |
Anticuerpos anti-FGF19 y métodos de uso de los mismos
|
|
WO2007142241A1
(ja)
*
|
2006-06-05 |
2007-12-13 |
Hiroshima University |
抗ｃｄ３８抗体を細胞表面に有する免疫担当細胞
|
|
EP1918376A1
(en)
*
|
2006-11-03 |
2008-05-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
|
|
CL2008000947A1
(es)
*
|
2007-04-02 |
2008-10-10 |
Genentech Inc |
Uso de un antagonista de la proteina beta-klotho (klb) para tratar trastornos asociados a la expresion o actividad de klb.
|
|
US8236307B2
(en)
|
2007-08-03 |
2012-08-07 |
Genentech, Inc. |
Humanized anti-FGF19 antagonists and methods using same
|
|
US20090309617A1
(en)
*
|
2007-08-24 |
2009-12-17 |
Ye Fang |
Biosensor antibody functional mapping
|
|
US20090226459A1
(en)
*
|
2008-01-29 |
2009-09-10 |
Cold Spring Harbor Laboratory |
Role of fgf-19 in cancer diagnosis and treatment
|
|
CA2722854A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Wntresearch Ab |
Restoration of estrogen receptor-.alpha. activity
|
|
CA2727278A1
(en)
|
2008-06-16 |
2010-01-21 |
Immunogen, Inc. |
Novel synergistic effects
|
|
FR2933702A1
(fr)
*
|
2008-07-08 |
2010-01-15 |
Sanofi Aventis |
Antagonistes specifiques du recepteur fgf-r4
|
|
WO2010006214A1
(en)
*
|
2008-07-09 |
2010-01-14 |
Ambrx, Inc. |
Fgf-21 neutralizing antibodies and their uses
|
|
EP2318529B1
(en)
|
2008-08-04 |
2017-10-18 |
Five Prime Therapeutics, Inc. |
Fgfr extracellular domain acidic region muteins
|
|
WO2010033913A1
(en)
*
|
2008-09-22 |
2010-03-25 |
Icb International, Inc. |
Antibodies, analogs and uses thereof
|
|
US20100136584A1
(en)
*
|
2008-09-22 |
2010-06-03 |
Icb International, Inc. |
Methods for using antibodies and analogs thereof
|
|
US8445445B2
(en)
|
2009-09-15 |
2013-05-21 |
Five Prime Therapeutics, Inc. |
Method of promoting hair growth using FGFR4 extracellular domains
|
|
KR101952453B1
(ko)
*
|
2009-10-15 |
2019-02-26 |
제넨테크, 인크. |
수용체 특이성이 변경된 키메라 섬유모세포 성장 인자
|
|
LT2498799T
(lt)
|
2009-11-13 |
2016-11-10 |
Five Prime Therapeutics, Inc. |
Fgfr1 ekstraląstelinio domeno baltymų panaudojimas gydymui vėžio su nuo ligando priklausančiomis, aktyvuojančiomis fgfr2 mutacijomis
|
|
CN102770456B
(zh)
*
|
2009-12-04 |
2018-04-06 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体、抗体类似物、组合物和方法
|
|
WO2011084711A2
(en)
|
2009-12-17 |
2011-07-14 |
Five Prime Therapeutics, Inc. |
Hair growth methods using fgfr3 extracellular domains
|
|
JP4881428B2
(ja)
*
|
2009-12-25 |
2012-02-22 |
株式会社東芝 |
電子機器
|
|
US8481038B2
(en)
|
2010-11-15 |
2013-07-09 |
Five Prime Therapeutics, Inc. |
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
|
|
US8951972B2
(en)
|
2010-12-09 |
2015-02-10 |
Five Prime Therapeutics, Inc. |
FGFR1 extracellular domain combination therapies for lung cancer
|
|
JP6211931B2
(ja)
|
2011-03-09 |
2017-10-11 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
モノクローナル抗体を作製するための方法および試薬
|
|
US20140294820A1
(en)
*
|
2011-06-24 |
2014-10-02 |
University Of Miami |
Fibroblast growth factor receptor inhibition for the treatment of disease
|
|
CN107823630A
(zh)
|
2011-11-14 |
2018-03-23 |
戊瑞治疗有限公司 |
治疗癌症的方法
|
|
US10112987B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an amyloid-beta peptide
|
|
US10112988B2
(en)
|
2012-01-09 |
2018-10-30 |
Icb International, Inc. |
Methods of assessing amyloid-beta peptides in the central nervous system by blood-brain barrier permeable peptide compositions comprising a vab domain of a camelid single domain heavy chain antibody against an anti-amyloid-beta peptide
|
|
JP2015506944A
(ja)
*
|
2012-01-18 |
2015-03-05 |
ジェネンテック， インコーポレイテッド |
Ｆｇｆ１９修飾薬を使用する方法
|
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
|
SG11201408538PA
(en)
|
2012-07-13 |
2015-02-27 |
Roche Glycart Ag |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
|
JP6499079B2
(ja)
|
2012-11-13 |
2019-04-10 |
バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ |
クローディンを発現するガン疾患を処置するための剤
|
|
TN2016000115A1
(en)
|
2013-10-25 |
2017-07-05 |
Novartis Ag |
Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors.
|
|
PL3082858T3
(pl)
*
|
2013-12-20 |
2021-09-27 |
Angiobiomed Gmbh |
Środek wiążący adrenomedulinę do zastosowania w terapii nowotworu
|
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
|
JP6585167B2
(ja)
|
2014-10-03 |
2019-10-02 |
ノバルティス アーゲー |
Ｆｇｆｒ４阻害剤としての縮環二環式ピリジル誘導体の使用
|
|
RU2729161C2
(ru)
*
|
2014-10-23 |
2020-08-04 |
ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. |
Фармацевтические композиции, содержащие варианты пептидов, и способы их применения
|
|
AU2016238436A1
(en)
|
2015-03-25 |
2017-08-17 |
Novartis Ag |
Formylated N-heterocyclic derivatives as FGFR4 inhibitors
|
|
ES2972458T3
(es)
|
2016-02-10 |
2024-06-12 |
Bioinvent Int Ab |
Combinación de anticuerpo humano anti-FGFR4 y sorafenib
|
|
US10813933B2
(en)
*
|
2016-05-17 |
2020-10-27 |
Japanese Foundation For Cancer Research |
Therapeutic agent for lung cancer that has acquired EGFR-TKI resistance
|
|
WO2018055503A1
(en)
|
2016-09-20 |
2018-03-29 |
Novartis Ag |
Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
|
|
SG11201903911UA
(en)
|
2016-11-02 |
2019-05-30 |
Novartis Ag |
Combinations of fgfr4 inhibitors and bile acid sequestrants
|
|
US20190218285A1
(en)
*
|
2018-01-18 |
2019-07-18 |
Molecular Cloning Laboratories (MCLAB) LLC |
Long-Acting Therapeutic Fusion Proteins
|
|
CN109251983B
(zh)
*
|
2018-08-15 |
2022-03-25 |
深圳市罗湖区人民医院 |
Frs2基因的拷贝数扩增及其应用、检测拷贝数扩增的特异性引物对
|
|
MY195550A
(en)
|
2018-10-29 |
2023-01-31 |
Hoffmann La Roche |
Antibody Formulation
|
|
EA202191870A1
(ru)
*
|
2019-02-02 |
2021-12-15 |
Хуахуэй Хэлс Лтд. |
Антитела к fgf19
|
|
EP3865155B1
(en)
*
|
2020-02-13 |
2022-11-30 |
Orano Med |
Process for site-specific modification of an antibody
|
|
CN116726005B
(zh)
*
|
2022-03-03 |
2026-02-13 |
上海市第六人民医院 |
一种治疗运动损伤的药物及筛选方法和应用
|
|
KR20250012564A
(ko)
|
2022-05-19 |
2025-01-24 |
타이라 바이오사이언시스, 인크. |
Ppar 효현제 및 fgfr4 저해제를 이용한 치료법
|
|
EP4509142A1
(en)
|
2023-08-16 |
2025-02-19 |
Ona Therapeutics S.L. |
Fgfr4 as target in cancer treatment
|